Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in Hypertension: The MESA Study | Zendy

Ehimare Akhabue | Zendy; ThanhHuyen T. Vu | Zendy; Anand Vaidya | Zendy; Erin D. Michos | Zendy; Ian H. de Boer | Zendy; Bryan Kestenbaum | Zendy; Matthew Allison | Zendy; Moysés Szklo | Zendy; Pamela Ouyang | Zendy; Clyde W. Yancy | Zendy; Myles Wolf | Zendy; Tamara Isakova | Zendy; Mercedes R. Carnethon | Zendy

Open Access

Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in Hypertension: The MESA Study

Author(s) -

Ehimare Akhabue,

ThanhHuyen T. Vu,

Anand Vaidya,

Erin D. Michos,

Ian H. de Boer,

Bryan Kestenbaum,

Matthew Allison,

Moysés Szklo,

Pamela Ouyang,

Clyde W. Yancy,

Myles Wolf,

Tamara Isakova,

Mercedes R. Carnethon

Publication year - 2018

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1093/ajh/hpy142

Subject(s) - medicine , hazard ratio , aldosterone , renin–angiotensin system , proportional hazards model , endocrinology , confidence interval , cardiology , heart failure , angiotensin ii , blood pressure

Higher fibroblast growth factor-23 (FGF23) concentrations have been found to be associated with incident heart failure (HF). Experimental data suggest FGF23 directly stimulates myocardial hypertrophy. FGF23 may also enhance renin-angiotensin-aldosterone system activity. Whether FGF23 is associated with increased HF risk in populations with hypertension and whether this association is weaker in the presence of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research